221.82MMarket Cap-737P/E (TTM)
4.670High4.515Low609.00KVolume4.650Open4.690Pre Close2.79MTurnover1.52%Turnover RatioLossP/E (Static)48.54MShares11.95052wk High1.51P/B183.20MFloat Cap4.25052wk Low--Dividend TTM40.09MShs Float82.490Historical High--Div YieldTTM3.31%Amplitude4.250Historical Low4.585Avg Price1Lot Size
uniQure NV Stock Forum
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease
uniQure has received the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for its investigational gene therapy, AMT-130, for Huntington’s disease. This designation is based on 24-month interim data from Phase I/II clinical trials released in December 2023 and represents a significant milestone.
AMT-130 is the firs...
No comment yet